|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Stereotactic body radiation therapy for non-small cell lung cancer:A review显示文摘Stereotactic body radiation therapy(SBRT) is the treatment of choice for medically inoperable patients with early stage non-small cell lung cancer(NSCLC). A literature search primarily based on PubMed electronic databases was completed in July 2018. Inclusion and exclusion criteria were determined prior to the search, and only prospective clinical trials were included. Nineteen trials from 2005 to 2018 met the inclusion criteria, reporting the outcomes of 1434 patients with central and peripheral early stage NSCLC. Patient eligibility,prescription dose and delivery, and follow up duration varied widely. Threeyears overall survival ranged from 43% to 95% with loco-regional control of up to 98% at 3 years. Up to 33% of patients failed distantly after SBRT at 3 years. SBRT was generally well tolerated with 10%-30% grade 3-4 toxicities and a few treatment-related deaths. No differences in outcomes were observed between conventionally fractionated radiation therapy and SBRT, central and peripheral lung tumors, or inoperable and operable patients. SBRT remains a reasonable treatment option for medically inoperable and select operable patients with early stage NSCLC. SBRT has shown excellent local and regional control with toxicity rates equivalent to surgery. Decreasing fractionation schedules have been consistently shown to be both safe and effective. Distant failure is common, and chemotherapy may be considered for select patients. However, the survival benefit of additional interventions, such as chemotherapy, for early stage NSCLC treated with SBRT remains unclear. | Kavitha M Prezzano Sung Jun Ma Gregory M Hermann Charlotte I Rivers Jorge A Gomez-Suescun Anurag K Singh | 2019 | World Journal of Clinical Oncology2019，10，1： | 10 |
| 2 | Long-term outcomes of interventions for radiation-induced xerostomia:A review显示文摘Xerostomia, or dry mouth, is a significant problem affecting quality of life in patients treated with radiation therapy for head and neck cancer. Strategies for reduction of xerostomia burden vary widely, with options including: sialagogue medications, saliva substitutes, acupuncture, vitamins, hyperbaric oxygen,submandibular gland transfer, and acupuncture or associated treatments. In this review, we sought to evaluate long-term outcomes of patients treated with various interventions for radiation-induced xerostomia. A literature search was performed using the terms 'xerostomia' and 'radiation' or 'radiotherapy'; all prospective clinical trials were evaluated, and only studies that reported 1 year follow up were included. The search results yielded 2193 studies, 1977 of which were in English. Of those, 304 were clinical trials or clinical studies. After abstract review, 23 trials were included in the review evaluating the following treatment modalities: pilocarpine(three); cevimeline(one); amifostine(eleven);submandibular gland transfer(five); acupuncture like transcutaneous electrical nerve stimulation(ALTENS)(one); hyperbaric oxygen(one); and acupuncture(one). Pilocarpine, cevimeline, and amifostine have been shown in some studies to improve xerostomia outcomes, at the cost of toxicity. ALTENS has similar efficacy with fewer side effects. Submandibular gland transfer is effective but requires an elective surgery, and thus may not always be appropriate or practical.The use of intensity-modulated radiation therapy, in addition to dose deescalation in select patients, may result in fewer patients with late xerostomia,reducing the need for additional interventions. | Sung Jun Ma Charlotte I Rivers Lucas M Serra Anurag K Singh | 2019 | World Journal of Clinical Oncology2019，10，1： | 4 |
| 3 | Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage Ⅲ nonsmall cell lung cancer显示文摘AIM: To prospectively determine the safety and tolerability of oral L-selenomethionine(SLM) with concurrent chemoradiation(CCRT) for Stage Ⅲ non-small cell lung cancer(NSCLC) and estimate if the incidence and/or severity of adverse events could be reduced by its use.METHODS: Sixteen patients with stage Ⅲ NSCLC were accrued to this single arm, phase Ⅱ study. CCRT consisted of radiation given at 2 Gy per fraction for 30-33 fractions, 5 d per week with concurrent weekly Ⅳ paclitaxel 50 mg/m2 followed by carboplatin dosed at an area under the time-concentration curve of 2. SLM was dosed in a loading phase at 4800 μg twice daily for one week prior to CCRT followed by once daily dosing during treatment. RESULTS: No selenium-related toxicity was observed. Analysis revealed grade 3 or higher esophagitis in 3 of 16 patients(19%), pneumonitis in 0, leukopenia in 2(12.5%), and anemia in 1(6%); the latter two were significantly reduced when compared to the protocolstated expected rate of 35%(P = 0.045 for leukopenia, and P < 0.01 for anemia). Median overall survival was 14.9 mo and median failure-free survival was 9 mo(95%CI: 3.3-21.5).CONCLUSION: There may be some protective benefit of selenium in the setting of CCRT for inoperable NSCLC. The data suggests decreased rates of myelosuppression when compared to similarly-treated historical and contemporary controls. Further evaluation of selenium in this setting may be warranted. | Michael Mix Nithya Ramnath Jorge Gomez Charles de Groot Saju Rajan Shiva Dibaj Wei Tan Youcef Rustum Michael B Jameson Anurag K Singh | 2015 | World Journal of Clinical Oncology2015，6，5： | 4 |
| 4 | A prospective trial of volumetric intensity-modulated arc therapy vs conventional intensity modulated radiation therapy in advanced head and neck cancer显示文摘AIM: To prospectively compare volumetric intensitymodulated arc therapy(VMAT) and conventional intensity-modulated radiation therapy(IMRT) in coverage of planning target volumes and avoidance of multiple organs at risk(OARs) in patients undergoing definitive chemoradiotherapy for advanced(stage Ⅲ or Ⅳ)squamous cell cancer of the head and neck. METHODS: Computed tomography scans of 20 patients with advanced tumors of the larynx, naso-, oroand hypopharynx were prospectively planned using IMRT(7 field) and VMAT using two arcs. Calculated doses to planning target volume(PTV) and OAR were compared between IMRT and VMAT plans. Dose-volume histograms(DVH) were utilized to obtain calculated doses to PTV and OAR, including parotids, cochlea,spinal cord, brainstem, anterior tongue, pituitary and brachial plexus. DVH's for all structures were compared between IMRT and VMAT plans. In addition the planswere compared for dose conformity and homogeneity. The final treatment plan was chosen by the treating radiation oncologist. RESULTS: VMAT was chosen as the ultimate plan in 18 of 20 patients(90%) because the plans were thought to be otherwise clinically equivalent. The IMRT plan was chosen in 2 of 20 patients because the VMAT plan produced concentric irradiation of the cord which was not overcome even with an avoidance structure. For all patients, VMAT plans had a lower number of average monitor units on average(MU = 542.85) than IMRT plans(MU = 1612.58)(P < 0.001). Using the conformity index(CI), defined as the 95% isodose volume divided by the PTV, the IMRT plan was more conformal with a lower conformity index(CI = 1.61) than the VMAT plan(CI = 2.00)(P = 0.003). Dose homogeneity, as measured by average standard deviation of dose distribution over the PTV, was not different with VMAT(1.45 Gy) or IMRT(1.73 Gy)(P = 0.069). There were no differences in sparing organs at risk.CONCLUSION: In this prospective study, VMAT plans were chosen over IMRT 90% of the time. Compared to IMRT, VMAT plans used only one third of the MUs, had shorter treatment times, and similar sparing of OAR. Overall, VMAT provided similar dose homogeneity but less conformity in PTV irradiation compared to IMRT. This difference in conformity was not clinically significant. | Simon D Fung-Kee-Fung Rachel Hackett Lee Hales Graham Warren Anurag K Singh | 2012 | World Journal of Clinical Oncology2012，3，4： | 2 |
| 5 | Editorial: Post Operative Cognitive Dysfunction显示文摘 | Tej K Kaul Anurag Tawari | 2008 | J Anaesth Clin Pharmacol2008，24，2： | 1 |
| 6 | Relay selection for geographical forwarding in sleep - wake cycling wireless sensor networics显示文摘 | Naveen K P Anurag Kumar | 2013 | IEEE Transactions on Mobile Computing2013，11，3： | 1 |
| 7 | Latex:a model for understanding mechanisms,ecology,and evolution of plant defense against herbivory显示文摘 | Anurag A A Konno K | 2009 | Ann Rev Ecol Syst2009，40，1： | 1 |
| 8 | Comparative performance analysis of versions of TCP in a local network with a lossy link显示文摘 | Anurag K | 1998 | IEEE/ACM Transactions on Networking1998，6，4： | 1 |
| 9 | Stereotactic radiotherapy for prostate cancer:A review and future directions显示文摘Prostate cancer affects over 200000 men annually in the United States alone.The role of conventionally fractionated external beam radiation therapy (RT) is well established as a treatment option for eligible prostate cancer patients; however,the use of stereotactic body radiotherapy (SBRT) in this setting is less well defined.Within the past decade,there have been a number of studies investigating the feasibility of SBRT as a potential treatment option for prostate cancer patients.SBRT has been well studied in other disease sites,and the shortened treatment course would allow for greater convenience for patients.There may also be implications for toxicity as well as disease control.In this review we present a number of prospective and retrospective trials of SBRT in the treatment of prostate cancer.We focus on factors such as biochemical progression-free survival,prostate specific antigen (PSA) response,and toxicity in order to compare SBRT to established treatment modalities.We also discuss future steps that the clinical community can take to further explore this new treatment approach.We conclude that initial studies examining the use of SBRT in the treatment of prostate cancer have demonstrated impressive rates of biochemical recurrencefree survival and PSA response,while maintaining a relatively favorable acute toxicity profile,though long-term follow-up is needed. | Yusef A Syed Ami K Patel-Yadav Charlotte Rivers Anurag K Singh | 2017 | World Journal of Clinical Oncology2017，8，5： | 1 |
| 10 | Aspect-oriented programming显示文摘 | GREGOR K JOHN L ANURAG M | 1997 | Springer-Verlag LNCS1997，1241，1： | 1 |
| 11 | Specificity of constitutive and induced resistance:pigment glands influence mites and caterpillars on cotton plants显示文摘 | Richard K | 2000 | Entomologia Experimentalis et Applicata2000，96，： | 1 |
| 12 | Evolutionary algorithm based optimization for power quality disturbances classification using support vector machines显示文摘 | Mlihir N M Anurag K Aurobinda R | 2010 | International Journal of Control Automation and Systems2010，8，6： | 1 |
| 13 | Effect of enzymatic Hydrolysis on the juice yield from bael fruit(Aegle marmelos Correa) pulp显示文摘 | Anurag Singh Sanjay Kumar H K Sharma | 2012 | Food Technology2012，，7： | 1 |
| 14 | A smallscale multi - effect distillation unit for rural micro enterprises 显示文摘 | SEN P K PADMA VASUDEVAN MUDGAL ANURAG | 2011 | Desalination2011，279，3： | 1 |
| 15 | Impact of conditioning regimen on peripheral blood hematopoietic cell transplant显示文摘AIM To investigate infused hematopoietic cell doses and their interaction with conditioning regimen intensity +/-total body irradiation(TBI) on outcomes after peripheral blood hematopoietic cell transplant(PBHCT).METHODS Our retrospective cohort included 247 patients receiving a first, T-replete, human leukocyte antigen-matched allogeneic PBHCT and treated between 2001 and2012. Correlations were calculated using the Pearson product-moment correlation coefficient. Overall survival and progression free survival curves were generated using the Kaplan-Meier method and compared using the log-rank test.RESULTS Neutrophil engraftment was significantly faster after reduced intensity TBI based conditioning [reduced intensity conditioning(RIC) + TBI] and > 4 × 10~6 CD34+cells/kg infused. A higher total nucleated cell dose led to a higher incidence of grade II-IV acute graft-versus-host disease in the myeloablative + TBI regimen group(P = 0.03), but no significant difference in grade III-IV graft-versus-host disease. A higher total nucleated cell dose was also associated with increased incidence of moderate/severe chronic graft-versus-host disease, regardless ofconditioning regimen. Overall and progression-free survival were significantly better in patients with a RIC + TBI regimen and total nucleated cell dose > 8 ×10~8/kg(3 years, overall survival: 70% vs 38%, P = 0.02, 3 years, progression free survival: 64% vs 38%, P = 0.02).CONCLUSION TBI and conditioning intensity may alter the relationship between infused cell doses and outcomes after PBHCT. Immune cell subsets may predict improved survival after unmanipulated PBHCT. | Michael Burns Anurag K Singh Carrie C Hoefer Yali Zhang Paul K Wallace George L Chen Alexis Platek Timothy B Winslow Austin J Iovoli Christopher Choi Maureen Ross Philip L McCarthy Theresa Hahn | 2019 | World Journal of Clinical Oncology2019，10，2： | 1 |
| 16 | Sacral never stimulation for the management of voiding dysfunction显示文摘 | Anurag K Mark D Penelope A | 2000 | Rev Urol2000，46，： | 1 |
| 17 | Editorial: Post Operative Cognitive Dysfunction显示文摘 | TEJ K KAUL Anurag Tawari | 2008 | J Anaesth Clin Pharmacol2008，24，2： | 1 |
| 18 | Tracing rays through graded-index media: a new method显示文摘 | Anurag Sharma D Vizia Kumar A K Ghatak | 1982 | Appl Opt1982，21，6： | 1 |
| 19 | Photoluminescence study of Y2O3:Er3+-Eu3+-Yb3+phosphor for lighting and sensing applications显示文摘 | VINEET K R ANURAG P RIYA D | 2013 | Journal of Applied Physics2013，，08： | 1 |
| 20 | Synthesis and antiangiogenic activity of some novel analogues of combretastatin A4 显示文摘 | ANURAG ROY R K SHARMA P | 2009 | lnt J Pharm Tech Res2009，1，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员